These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 27841867)

  • 1. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.
    Thompson JM; Alvarez A; Singha MK; Pavesic MW; Nguyen QH; Nelson LJ; Fruman DA; Razorenova OV
    Mol Cancer Ther; 2018 Aug; 17(8):1781-1792. PubMed ID: 29720560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
    Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
    Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
    Shang D; Liu Y; Yang P; Chen Y; Tian Y
    Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
    Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
    Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor.
    Wacker I; Sachs M; Knaup K; Wiesener M; Weiske J; Huber O; Akçetin Z; Behrens J
    Mol Cell Biol; 2009 Apr; 29(7):1707-18. PubMed ID: 19158274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
    Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
    Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
    Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
    PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.
    Razorenova OV; Castellini L; Colavitti R; Edgington LE; Nicolau M; Huang X; Bedogni B; Mills EM; Bogyo M; Giaccia AJ
    Mol Cell Biol; 2014 Feb; 34(4):739-51. PubMed ID: 24344197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
    Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
    Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.